Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation (NYSE: ITGR) for allegedly misleading investors regarding its competitive position and sales performance in the EP manufacturing market during the specified class period from July 25, 2024, to October 22, 2025 [7]. Allegation Details - The complaint claims that the defendants failed to disclose that the company materially overstated its competitive position within the growing EP manufacturing market [3]. - It is alleged that despite the company's claims of strong visibility into customer demand, it was experiencing a sustained deterioration in sales related to two of its EP devices [3]. - The company mischaracterized its EP devices as a long-term growth driver for its C&V segment, leading to materially false and misleading statements about its business, operations, and prospects [3]. Next Steps - Investors who purchased or acquired Integer shares and suffered losses are encouraged to contact the law firm for more information and to discuss their legal rights [4]. - There is no cost or obligation for investors to reach out regarding their potential claims [4]. - Investors have until February 9, 2026, to apply to the Court to be appointed as lead plaintiff in the lawsuit [7].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Navan, Inc. for possible violations of federal securities laws and unlawful business practices affecting stockholders [1]. Investigation Details - The investigation is focused on whether Navan has engaged in unlawful activities that may have led to financial losses for investors [2]. Financial Performance - Navan conducted its IPO on October 30, 2025, selling approximately 36.9 million shares at $25.00 per share [6]. - The company reported a GAAP loss from operations of $79 million for Q3 fiscal 2026, compared to a loss of $19 million in the same period the previous year [6]. - The GAAP operating margin was reported at -41%, a significant decline from -13% in the same quarter of the previous year [6]. Management Changes - Following the financial results, Navan's CFO stepped down just six weeks post-IPO, receiving benefits including accelerated vesting of restricted stock units and a cash payment of $3.7 million [6]. Stock Price Reaction - On December 16, 2025, Navan's stock price fell by $1.74, or 11.9%, closing at $12.90 per share, indicating a negative market reaction to the financial disclosures and management changes [6].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Lakeland Industries, Inc. for possible violations of federal securities laws and unlawful business practices affecting stockholders [1][2]. Investigation Details - The investigation is focused on whether Lakeland has engaged in unlawful business practices that may have led to financial losses for investors [1][2]. Financial Performance - Lakeland reported third-quarter earnings on December 9, 2025, with net sales of $47.6 million for Q3 2026, and an adjusted EBITDA of $200,000, reflecting a decrease of $4.5 million or 95% compared to the prior year [6]. - The company experienced a net loss of $16 million, equating to ($1.64) per basic and diluted share, in contrast to a net income of $100,000 or $0.01 per share in the same quarter of the previous year [6]. - Following the earnings report, Lakeland's stock price dropped by $5.85 per share, or 38.97%, closing at $9.16 per share on December 10, 2025 [6]. Management Commentary - CEO James Jenkins attributed the poor financial results partly to "delays in certification," indicating that the company anticipated certification to occur in March 2026 [6].

Core Viewpoint - A class action lawsuit has been filed against Telix Pharmaceuticals Limited for allegedly making false and misleading statements regarding its business operations and prospects during the Class Period from February 21, 2025, to August 28, 2025 [3][7]. Allegation Details - The lawsuit claims that defendants materially overstated the progress of Telix's prostate cancer therapeutic candidates [3]. - It is alleged that the quality of Telix's supply chain and partners was also overstated [3]. - As a result of these misrepresentations, statements about Telix's business and operations were materially false and misleading, leading to investor damages when the true details emerged [3]. Next Steps - Investors who purchased Telix shares and suffered losses are encouraged to contact the law firm for more information or to discuss their rights [4]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is January 9, 2026 [7]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation [5]. - The firm has offices in New York, California, and South Carolina, and specializes in commercial and securities litigation [5].

Core Viewpoint - A class action lawsuit has been filed against F5, Inc. for allegedly providing misleading information regarding its security capabilities, which led to significant financial losses for investors during the specified class period [2][7]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals and entities that purchased F5 securities between October 28, 2024, and October 27, 2025, inclusive [2]. - Investors have until February 17, 2026, to apply to the Court to be appointed as lead plaintiff in the lawsuit [2]. Group 2: Allegations - The complaint alleges that F5 made overwhelmingly positive statements while concealing material adverse facts about its security capabilities, specifically regarding a significant security breach affecting key offerings [7]. - The breach reportedly impacted F5's ability to capitalize on the security market, leading to reduced sales and renewals, elongated sales cycles, and increased expenses for remediation efforts [7]. Group 3: Financial Impact - On October 27, 2025, F5 announced fourth quarter fiscal year 2025 results that fell significantly below market growth expectations for fiscal 2026 due to the security breach [7]. - Following the announcement, F5's stock price dropped from $290.41 per share to $258.76 per share, a decline of 10.9% within two days [7].

Core Viewpoint - A class action lawsuit has been filed against Perrigo Company plc for failing to disclose significant issues related to its infant formula business, leading to investor losses during the specified class period [2][8]. Allegation Details - The lawsuit alleges that Perrigo did not disclose the following critical issues: 1. The infant formula business acquired from Nestlé suffered from significant underinvestment in maintenance and operational improvements [8]. 2. Perrigo needed to make substantial capital and operational expenditures beyond previously stated cost estimates to remediate the infant formula business [8]. 3. There were significant manufacturing deficiencies in the facility for the infant formula business [8]. 4. As a result of these issues, the Company's financial results, including earnings and cash flow, were overstated [8]. Financial Impact - On November 5, 2025, Perrigo announced disappointing financial results for Q3 2025, leading to a significant reduction in its fiscal year 2025 outlook due to "infant formula industry dynamics" [8]. - The same day, Perrigo initiated a strategic review of its infant formula business, reassessing a previously announced investment of $240 million, indicating the business had become "less strategic" [8]. - Following this announcement, Perrigo's stock price fell by $5.09, or 25.2%, closing at $15.10 per share on November 5, 2025 [8].

Core Viewpoint - A class action lawsuit has been filed against Firefly Aerospace Inc. for allegedly misleading investors regarding the company's IPO and subsequent financial performance [7]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals and entities who purchased Firefly common stock during the IPO on August 7, 2025, and those who acquired shares between August 7, 2025, and September 29, 2025 [7]. - Investors have until January 12, 2026, to apply to the Court to be appointed as lead plaintiff in the lawsuit [7]. Group 2: Allegations - The complaint alleges that the Offering Documents related to the IPO were negligently prepared, failing to disclose critical information about the company's operations and growth prospects [7]. - Specific allegations include overstated demand for Firefly's Spacecraft Solutions, overstated operational readiness of the Alpha rocket program, and the potential negative impact on the company once these issues were revealed [7]. Group 3: Financial Impact - Following disappointing financial results reported on September 22, 2025, Firefly's stock price fell by $7.58 per share, or 15.31%, closing at $41.94 on September 23, 2025 [7]. - On September 29, 2025, after disclosing an incident with the Alpha Flight 7 rocket, the stock price dropped by $7.66 per share, or 20.73%, closing at $29.30 on September 30, 2025 [7]. - As of the filing of the complaint, Firefly's stock continues to trade significantly below the $45.00 per share Offering price, indicating substantial losses for investors [7].

Core Viewpoint - A class action lawsuit has been filed against CarMax, Inc. for allegedly making false and misleading statements regarding its growth prospects during the Class Period from June 20, 2025, to September 24, 2025, leading to investor losses [5]. Allegation Details - The lawsuit claims that CarMax's management overstated the company's growth potential, attributing earlier growth in fiscal year 2026 to temporary factors related to customer behavior influenced by tariff speculation [5]. - It is alleged that the statements made by the defendants about CarMax's business operations and future prospects were materially false and misleading [5]. Financial Performance - On April 10, 2025, CarMax reported its fourth quarter and fiscal year 2025 results, which missed consensus estimates, leading to a stock price drop of $13.61, or 17%, closing at $66.45 per share [5]. - On September 25, 2025, CarMax disclosed significant declines in revenue and profit, including a 6.0% revenue decline, a 7.2% decline in total retail used vehicle revenues, and a 5.6% decline in total gross profit, resulting in a further stock price drop of $11.45, or 20.1%, closing at $45.60 per share [5].

Core Viewpoint - A class action lawsuit has been filed against DexCom, Inc. for allegedly making false and misleading statements regarding its products, particularly the G6 and G7 glucose monitoring devices, during the class period from July 26, 2024, to September 17, 2025 [2][3]. Group 1: Lawsuit Details - The lawsuit is filed in the United States District Court for the Southern District of New York on behalf of all individuals and entities who purchased DexCom securities during the specified class period [2]. - Investors have until December 26, 2025, to apply to be appointed as lead plaintiff in the lawsuit [2]. Group 2: Allegations - The complaint alleges that DexCom made unauthorized design changes to the G6 and G7 devices that were not approved by the FDA, which compromised their reliability and posed health risks to users [3]. - It is claimed that the enhancements to the G7 were overstated, and the company downplayed the severity of issues related to the devices, leading to increased regulatory scrutiny and potential legal repercussions [3]. Group 3: Next Steps for Investors - Investors who suffered losses or have information regarding the claims are encouraged to contact the law firm for further details and assistance [4].

Core Viewpoint - A class action lawsuit has been filed against Baxter International, Inc. for allegedly misleading investors regarding the safety and efficacy of its Novum LVP devices, which reportedly suffered systemic defects leading to serious patient risks [3][7]. Allegation Details - The lawsuit claims that Baxter failed to disclose systemic defects in the Novum LVP, which caused malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing risks of serious injury or death to patients [3]. - Baxter was allegedly aware of multiple device malfunctions, injuries, and deaths related to these defects but did not take adequate remedial measures [3]. - The company’s statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs are claimed to be materially false and misleading [3]. Next Steps - Investors who purchased Baxter shares and suffered losses are encouraged to contact the law firm for more information about their rights and potential claims [4][7]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is December 15, 2025 [7]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation across various courts [5].